Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate

International Journal of Antimicrobial Agents

Volumn 14, Issue 3, 2000, Pages 231-234

  Andersen, Leif P ^a   Colding, Hanne ^b   Kristiansen, Jette E ^c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Sønderborg Hospital   (Denmark)

Author keywords

Helicobacter pylori; Metronidazole; Omeprazole; Subcitrate

Indexed keywords

BISMUTH CITRATE; METRONIDAZOLE; OMEPRAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENTIATION; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS;

EID: 0034032702     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00133-3     Document Type: Article

References (21)

1. Megraud F., Brassens-Rabbe M.P., Denis F. et al. Seroepidemiology of Campylobacter pylori infection in various populations. J. Clin. Microbiol. 27:1989;1870-1873.
2. Andersen L.P., Rosenstock S.J., Bonnevie O. et al. Seroprevalence of immunoglobulin G, M, and A antibodies to Helicobacter pylori in an unselected Danish population. Am. J. Epidemiol. 143:1996;1157-1164.
3. Kosunen T.U., Hook J., Rautelin H.I. Age-dependent increase of Campylobacter pylori antibodies in blood donors. Scand. J. Gastroenterol. 24:1989;110-114.
4. Klein P.D., Graham D.Y., Gaillour A. et al. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet. 337:1991;1503-1506.
5. Kelly S.M., Pitcher M.C., Farmery S.M. et al. Isolation of Helicobacter pylori from faeces of patients with dyspepsia in the UK. Gastroenterology. 107:1994;1671-1674.
6. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1:1984;1311-1315.
7. Dunn B.E., Cohen H., Blaser M.J. Helicobacter pylori. Clin. Microbiol. Rev. 10:1997;720-741.
8. Andersen L.P., Nielsen H. Peptic ulcer: an infectious disease? Ann. Med. 25:1993;563-568.
9. Lynch D.A., Axon A.T. Helicobacter pylori, gastric cancer and gastric epithelial kinetics: a review. Eur. J. Gastroenterol. Hepatol. 7:1995;S17-S23.
10. Eidt S., Stolte M. The significance of Helicobacter pylori in relation to gastric cancer and lymphoma. Eur. J. Gastroenterol. Hepatol. 7:1995;318-321.
11. Hopkins R.J., Girardi L.S., Tumey E.A. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 110:1996;1244-1252.
12. Deltenre M., Jonas C., Otero J. et al. Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. J. Physiol. Pharmacol. 47:1996;59-69.
13. Bell G.D., Powell K.U., Burridge S.M. et al. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease. Q. J. Med. 86:1993;375-382.
14. Kristiansen J.E. Antimicrobial activity of non-antibiotics: unusual properties of non-antibiotic drugs create unexpected therapeutic possibilities and lead to new basic insights. Features. ASM News. 57:1991;135-139.
15. Andreasen J.J., Andersen L.P. In vitro susceptibility of Campylobacter pylori to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathol. Microbiol. lmmunol. Scand. Sect. B. 95:1987;147-149.
16. Belli W.A., Fryklund J. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Antimicrob. Agents Chemother. 39:1995;1717-1720.
17. lwahi T., Hiroshi H., Nakao M. et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob. Agents Chemother. 35:1991;490-496.
18. Labenz J., Tillenburg B., Peitz U. et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 110:1996;725-732.
19. Kristiansen J.E. Experiments to illustrate the effect of chlorpromazine on the permeability of the bacterial cell wall. Acta Pathol. Microbiol. Immunol. Scand. Sect. B. 87:1979;317-319.
20. Kristiansen J.E. Chlorpromazine: non-antibiotics with antimicrobial activity - new insights in managing resistance? Curr. Opin. Invest. Drugs. 2:1993;587-591.
21. Kristiansen J.E., Amaral L. The potential management of resistant infections with non-antibiotics. J. Antimicrob. Chemother. 40:1997;319-327.